The role of CTGF in diabetic retinopathy

被引:84
作者
Klaassen, Ingeborg [1 ,2 ]
van Geest, Rob J. [1 ,2 ]
Kuiper, Esther J. [1 ,2 ]
van Noorden, Cornelis J. F. [1 ,2 ]
Schlingemann, Reinier O. [1 ,2 ,3 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Ocular Angiogenesis Grp, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands
[3] Royal Acad Sci, Netherlands Inst Neurosci, Amsterdam, Netherlands
关键词
Connective tissue growth factor; Pre-clinical diabetic retinopathy; Proliferative diabetic retinopathy; Extracellular matrix; Basal lamina thickening; Wound healing; Angio-fibrotic switch; TISSUE GROWTH-FACTOR; GLYCATION END-PRODUCTS; ACTIVATOR INHIBITOR TYPE-1; BASEMENT-MEMBRANE; FACTOR-BETA; GENE-EXPRESSION; EXTRACELLULAR-MATRIX; CCN FAMILY; INTRAVITREAL BEVACIZUMAB; DOWN-REGULATION;
D O I
10.1016/j.exer.2014.10.016
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Connective tissue growth factor (CTGF, CCN2) contributes to fibrotic responses in diabetic retinopathy, both before clinical manifestations occur in the pre-clinical stage of diabetic retinopathy (PCDR) and in proliferative diabetic retinopathy (PDR), the late clinical stage of the disease. CTGF is a secreted protein that modulates the actions of many growth factors and extracellular matrix (ECM) proteins, leading to tissue reorganization, such as ECM formation and remodeling, basal lamina (BL) thickening, pericyte apoptosis, angiogenesis, wound healing and fibrosis. In PCDR, CTGF contributes to thickening of the retinal capillary BL and is involved in loss of pericytes. In this stage, CTGF expression is induced by advanced glycation end products, and by growth factors such as vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)-beta. In PDR, the switch from neovascularization to a fibrotic phase the angio-fibrotic switch in PDR is driven by CTGF, in a critical balance with vascular endothelial growth factor (VEGF). We discuss here the roles of CTGF in the pathogenesis of DR in relation to ECM remodeling and wound healing mechanisms, and explore whether CTGF may be a potential novel therapeutic target in the clinical management of early as well as late stages of DR. (C) 2014 Elsevier Ltd. All rights reserved.
引用
收藏
页码:37 / 48
页数:12
相关论文
共 174 条
  • [1] Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc
    Abraham, D.
    [J]. RHEUMATOLOGY, 2008, 47 : V8 - V9
  • [2] Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β
    Abreu, JG
    Ketpura, NI
    Reversade, B
    De Robertis, EM
    [J]. NATURE CELL BIOLOGY, 2002, 4 (08) : 599 - 604
  • [3] Expression of angiogenic and fibrogenic factors in proliferative vitreoretinal disorders
    Abu El-Asrar A.M.
    Van den Steen P.E.
    Al-Amro S.A.
    Missotten L.
    Opdenakker G.
    Geboes K.
    [J]. International Ophthalmology, 2007, 27 (1) : 11 - 22
  • [4] Relationship between Vitreous Levels of Matrix Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic Retinopathy
    Abu El-Asrar, Ahmed M.
    Mohammad, Ghulam
    Nawaz, Mohd Imtiaz
    Siddiquei, Mohammad Mairaj
    Van den Eynde, Kathleen
    Mousa, Ahmed
    De Hertogh, Gert
    Opdenakker, Ghislain
    [J]. PLOS ONE, 2013, 8 (12):
  • [5] A single local injection of recombinant VEGF receptor 2 but not of tie2 inhibits retinal neovascularization in the mouse
    Agostini, HT
    Boden, K
    Unsöld, A
    Martin, G
    Hansen, LL
    Fiedler, U
    Esser, N
    Marmé, D
    [J]. CURRENT EYE RESEARCH, 2005, 30 (04) : 249 - 257
  • [6] Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor
    Aiello, LP
    Bursell, SE
    Clermont, A
    Duh, E
    Ishii, H
    Takagi, C
    Mori, F
    Ciulla, TA
    Ways, K
    Jirousek, M
    Smith, LEH
    King, GL
    [J]. DIABETES, 1997, 46 (09) : 1473 - 1480
  • [7] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
    AIELLO, LP
    AVERY, RL
    ARRIGG, PG
    KEYT, BA
    JAMPEL, HD
    SHAH, ST
    PASQUALE, LR
    THIEME, H
    IWAMOTO, MA
    PARK, JE
    NGUYEN, HV
    AIELLO, LM
    FERRARA, N
    KING, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
  • [8] Role of vascular endothelial growth factor in diabetic vascular complications
    Aiello, LP
    Wong, JS
    [J]. KIDNEY INTERNATIONAL, 2000, 58 : S113 - S119
  • [9] Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy
    Arevalo, J. F.
    Maia, M.
    Flynn, H. W., Jr.
    Saravia, M.
    Avery, R. L.
    Wu, L.
    Farah, M. Eid
    Pieramici, D. J.
    Berrocal, M. H.
    Sanchez, J. G.
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2008, 92 (02) : 213 - 216
  • [10] Babic AM, 1999, MOL CELL BIOL, V19, P2958